Everest Group enters the back half of August with a striking divergence: options traders are near their most bullish in a year, while short sellers quietly build positions for the third consecutive week.
The options signal is the standout story this week. The put/call ratio has dropped to 0.12 — almost touching its 52-week low of 0.11 — and sits well below its 20-day average of 0.18. That's a sharp rotation away from the defensive hedging that dominated the tape through mid-July, when the PCR ran above 1.3. Call volume is overwhelmingly dominant right now, reflecting the most one-sided bullish options positioning EG has seen all year. The shift has been rapid: the PCR was still above 0.5 as recently as July 20, before collapsing over the following four weeks as the stock stabilised.
The lending picture tells a quieter story. Short interest has nudged higher — up roughly 4.6% on the week to 3.8% of the free float — but the borrow market remains far from stressed. Availability is exceptionally loose at over 3,100%, meaning there are more than 37 million shares available to borrow against roughly 1.6 million already shorted. Cost to borrow has ticked up from its July trough but remains negligible at 0.52%. The short score, at 42.8, has drifted modestly higher over the past two weeks though sits in the bottom quarter of the universe by short-interest rank. This is incremental positioning, not a conviction short thesis.
The Street has spent the past three weeks lifting targets without upgrading ratings — a pattern worth noting. TD Cowen raised its target to $385 this morning while keeping a Hold. UBS and Wells Fargo both moved higher earlier in August, to $395 and $396 respectively, also neutral-rated. Post-earnings targets from Citigroup ($415) and Barclays ($430 Overweight) were the most constructive. The mean sits at $408, implying around 11% upside from the current $367.38. One holdout: Mizuho trimmed its target fractionally to $416 after the July 29 print. The overall direction of travel is upward, but the consensus is parked at neutral — analysts see the gap to fair value but aren't yet ready to endorse the stock as a buy. The PE has compressed about 0.3 turns over the past month to 6.4x, with price-to-book near 0.82 — cheap relative to history, though the 30% factor score on forward EPS growth suggests the earnings trajectory remains a drag on enthusiasm.
Earnings context sharpens the picture. The July 29 Q2 release produced a one-day decline of nearly 6% and a five-day move of roughly -6.4% — a consistent pattern of post-print selling. The next event is pencilled in for October 28. With the PCR close to its annual floor heading into that window, options traders appear to be leaning long rather than hedging, a notable contrast to the defensive stance they held through most of the second quarter.
Peers broadly tracked EG's muted weekly gain of 0.5%: ACGL added 0.7%, RNR led the group with 1.3%, while CB and L slipped slightly. SPNT was the week's outlier, up 4.4%, suggesting some rotation into smaller reinsurance names. EG's relative stability — down 4% on the month but holding near $367 — keeps it roughly in line with the broader group rather than breaking out in either direction.
The tension to watch into October is whether the bullish options skew persists as the next earnings date approaches, or whether the sector's habitual pre-print hedging reasserts itself given EG's recent history of post-announcement weakness.
See the live data behind this article on ORTEX.
Open EG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
